Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study DOI Creative Commons
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas

et al.

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 71, P. 96 - 108

Published: April 4, 2023

The World Health Organization has proposed that a search be made for alternatives to vaccines the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought assess: impact previous SSRI antidepressants on severity COVID-19 (risk hospitalisation, admission an intensive care unit [ICU], mortality), its influence susceptibility SARS-CoV-2 progression severe COVID-19. We conducted population-based multiple case-control in region north-west Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) 95%CIs calculated using multilevel logistic regression. collected data total 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised PCR+ 56,785 controls (without PCR+). Citalopram displayed statistically significant decrease risk hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) (aOR=0.64; 0.43-0.96, 0.032). Paroxetine was associated mortality (aOR=0.34; 0.12 - 0.94, 0.039). No class effect observed SSRIs overall, nor any other found remaining SSRIs. results this large-scale, real-world indicate that, citalopram, could candidate drug repurposed as preventive aimed at reducing patients' progressing stages disease.

Language: Английский

Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment DOI Open Access
Mario Gennaro Mazza, Mariagrazia Palladini, Sara Poletti

et al.

CNS Drugs, Journal Year: 2022, Volume and Issue: 36(7), P. 681 - 702

Published: June 21, 2022

Language: Английский

Citations

159
An overview on the treatments and prevention against COVID-19 DOI Creative Commons

Yunes Panahi,

Armita Mahdavi Gorabi,

Sona Talaei

et al.

Virology Journal, Journal Year: 2023, Volume and Issue: 20(1)

Published: Feb. 8, 2023

Abstract Background The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) continues to plague world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute distress syndrome), and death others. Although humans are currently being vaccinated with several candidate vaccines many countries, however, world still relying on hygiene measures, social distancing, approved drugs. Result There potential therapeutic agents pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, herbal agents. By an understanding of SARS-CoV-2 structure its infection mechanisms, vaccine candidates under development some various phases clinical trials. Conclusion This review describes agents, including biologic anti-inflammatory treatment patients. In addition reviewing that entered 4, 3, 2/3 trials, this also discusses platforms used develop COVID-19.

Language: Английский

Citations

51
Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions DOI Creative Commons
Kenji Hashimoto

Molecular Psychiatry, Journal Year: 2023, Volume and Issue: 28(9), P. 3625 - 3637

Published: Sept. 1, 2023

Abstract The human body harbors a diverse ecosystem of microorganisms, including bacteria, viruses, and fungi, collectively known as the microbiota. Current research is increasingly focusing on potential association between microbiota various neuropsychiatric disorders. resides in parts body, such oral cavity, nasal passages, lungs, gut, skin, bladder, vagina. gut gastrointestinal tract has received particular attention due to its high abundance role psychiatric neurodegenerative However, presents other tissues, though less abundant, also plays crucial immune system homeostasis, thus influencing development progression For example, imbalance associated periodontitis might increase risk for Additionally, studies using postmortem brain samples have detected widespread presence bacteria brains patients with Alzheimer’s disease. This article provides an overview emerging host disorders discusses future directions, underlying biological mechanisms, reliable biomarkers microbiota, microbiota-targeted interventions, this field.

Language: Английский

Citations

51
Arketamine, a new rapid-acting antidepressant: A historical review and future directions DOI Creative Commons
Jichun Zhang, Wei Yao, Kenji Hashimoto

et al.

Neuropharmacology, Journal Year: 2022, Volume and Issue: 218, P. 109219 - 109219

Published: Aug. 14, 2022

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine causes rapid onset and sustained antidepressant actions in treatment-resistant patients with major depressive disorder (MDD) other psychiatric disorders, such as bipolar post-traumatic stress disorder. is a racemic mixture consisting of (R)-ketamine (or arketamine) (S)-ketamine esketamine), (S)-enantiomer having greater affinity for the NMDAR. In 2019, an esketamine nasal spray by Johnson & was approved USA Europe depression. contrast, increasing number preclinical studies show that arketamine has potency longer-lasting antidepressant-like effects than rodents, despite lower binding Importantly, side effects, i.e., psychotomimetic dissociative abuse liability, are less those animals humans. An open-label study demonstrated MDD. A phase 2 clinical trial MDD underway. This designed to review brief history novel arketamine, molecular mechanisms underlying its actions, future directions. article part Special Issue on 'Ketamine Metabolites'.

Language: Английский

Citations

69
Sigma-1 receptor: A potential target for the development of antidepressants DOI
Yuming Wang,

Cong‐Yuan Xia,

Hongmei Jia

et al.

Neurochemistry International, Journal Year: 2022, Volume and Issue: 159, P. 105390 - 105390

Published: July 8, 2022

Language: Английский

Citations

41
Antidepressant psychopharmacology: is inflammation a future target? DOI
Francesco Benedetti, Raffaella Zanardi, Mario Gennaro Mazza

et al.

International Clinical Psychopharmacology, Journal Year: 2022, Volume and Issue: 37(3), P. 79 - 81

Published: March 31, 2022

Raised inflammatory setpoints have been associated with major depression and its detrimental consequences on brain function, as they lead to increased production of cytokines, changes in gene expression activated microglia. Three main lines evidence support immune-inflammatory mechanisms targets for the treatment depression. First, higher inflammation hampers response antidepressants, effective antidepressant decreases inflammation. Second, conventional antidepressants share immune-modulatory anti-inflammatory properties, which could affect during Third, treatments proved superior placebo randomized controlled trials. New new pharmacologic immune-mediated diseases identified tested several medical settings interest is warranted testing them antidepressants.

Language: Английский

Citations

39
Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis DOI Creative Commons
Kenji Hashimoto

Molecular Psychiatry, Journal Year: 2023, Volume and Issue: 28(12), P. 4968 - 4976

Published: July 4, 2023

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) infection has resulted in a serious public health burden worldwide. In addition to respiratory, heart, and gastrointestinal symptoms, patients infected with SARS-CoV-2 experience number of persistent neurological psychiatric known as long COVID or "brain fog". Studies autopsy samples from who died COVID-19 detected the brain. Furthermore, increasing evidence shows that Epstein-Barr virus (EBV) reactivation after might play role symptoms. Moreover, alterations microbiome contribute this article, author reviews detrimental effects on brain, biological mechanisms (e.g., EBV reactivation, changes gut, nasal, oral, lung microbiomes) underlying COVID. addition, discusses potential therapeutic approaches based gut-brain axis, including plant-based diet, probiotics prebiotics, fecal microbiota transplantation, vagus nerve stimulation, sigma-1 receptor agonist fluvoxamine.

Language: Английский

Citations

35
Arketamine for cognitive impairment in psychiatric disorders DOI Creative Commons
Kenji Hashimoto

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2023, Volume and Issue: 273(7), P. 1513 - 1525

Published: Feb. 14, 2023

Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) these patients, have not found to cognitive impairment. The N-methyl-D-aspartate receptor antagonist (R,S)-ketamine attracted attention as a rapidly acting antidepressant. In addition its robust antidepressant effects, suggested MDD BD, despite causing healthy control subjects. is racemic mixture of equal amounts (R)-ketamine (or arketamine) (S)-ketamine esketamine). Arketamine more potent antidepressant-like actions than esketamine rodents. Interestingly, arketamine, but esketamine, phencyclidine-induced deficits mice. Furthermore, arketamine ameliorate rodent offspring after maternal immune activation. the current article, it proposed that potential for treating disorders. Additionally, role gut-microbiome-brain axis disorders discussed.

Language: Английский

Citations

32
Causal associations between major depressive disorder and COVID-19 DOI Creative Commons
Ancha Baranova, Yi Zhao, Hongbao Cao

et al.

General Psychiatry, Journal Year: 2023, Volume and Issue: 36(2), P. e101006 - e101006

Published: April 1, 2023

We aimed to evaluate whether major depressive disorder (MDD) could aggravate the outcomes of coronavirus disease 2019 (COVID-19) or genetic liability COVID-19 trigger MDD.We assess bidirectional causal associations between MDD and COVID-19.We performed correlation Mendelian randomisation (MR) analyses potential three outcomes. Literature-based network analysis was conducted construct molecular pathways connecting found that has positive correlations with (rg: 0.10-0.15). Our MR indicated is associated increased risks infection (odds ratio (OR)=1.05, 95% confidence interval (CI): 1.00 1.10, p=0.039). However, did not confer any effects on MDD. Pathway identified a panel immunity-related genes may mediate links COVID-19.Our study suggests increase susceptibility COVID-19. findings emphasise need social support improve mental health intervention networks for people mood disorders during pandemic.

Language: Английский

Citations

26
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis DOI Creative Commons
Jiawen Deng, Daniel Rayner, Harikrishnaa Ba Ramaraju

et al.

Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 29(5), P. 578 - 586

Published: Jan. 16, 2023

Language: Английский

Citations

23